FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2921000372> ?p ?o ?g. }

• W2921000372 endingPage "547" @default.
• W2921000372 startingPage "547" @default.
• W2921000372 abstract "547 Background: Panitumumab (Pmab) is licensed for treatment in metastatic colorectal cancer (mCRC) patients with wild type KRAS mutation status (US) and wild type RAS (KRAS and NRAS) mutation status (most other countries). To resolve uncertainties about KRAS testing, a survey and medical records review (MRR) are being carried out in Europe in three rounds: the first two rounds (2012-2013) evaluated KRAS testing and round 3 is evaluating RAS testing. These studies are specific obligations in Europe for the conditional marketing authorization for Pmab. Here we present results of rounds 1 and 2. Methods: Eligible oncologists were contacted by telephone in nine European countries (France, Germany, Italy, Spain, Czech Republic, Netherlands, Belgium, Denmark, and Sweden). To be eligible, the physician was required to be a practicing oncologist and have prescribed Pmab to mCRC patients. Results: 299 of 301 (99.3%) oncologists participating in the survey were aware of the need to perform KRAS testing prior to first dose of Pmab and 294 (97.7%) were aware of patients’ KRAS mutation status prior to first dose. 283 of 301 (94.0%) did not prescribe Pmab to mCRC patients with mutant or unknown KRAS status. 164 physicians administered Pmab simultaneously with oxaliplatin-containing chemotherapy to patients and 10 (6.1%) to patients with mutant or unknown KRAS status. 306 patients from 79 participating oncologists were included in the MRR. 302 of 306 mCRC patients (98.7%) were tested for KRAS tumor status, known by the oncologist before first dose of Pmab. 299 of 302 patients (99.0%) had wild-type KRAS tumor status. 83 of 85 patients (97.6%) treated with Pmab and oxaliplatin-containing chemotherapy had wild-type KRAS tumor status. 55 of 56 linked pathology laboratories (98.2%) participated in a Quality Assurance scheme; all used a CE marked or otherwise validated KRAS detection method. Conclusions: Results from both studies show a high level of knowledge among oncologists of the need for KRAS testing in mCRC patients prior to treatment with Pmab and the contraindication with oxaliplatin-containing chemotherapy with mutant or unknown KRAS tumour status. The final round of this study evaluating RAS testing in Europe is currently underway." @default.
• W2921000372 created "2019-03-22" @default.
• W2921000372 creator A5020456711 @default.
• W2921000372 creator A5025634287 @default.
• W2921000372 creator A5031480761 @default.
• W2921000372 creator A5056028552 @default.
• W2921000372 creator A5067038598 @default.
• W2921000372 creator A5067647558 @default.
• W2921000372 creator A5069539916 @default.
• W2921000372 creator A5074765601 @default.
• W2921000372 creator A5090671983 @default.
• W2921000372 creator A5091162361 @default.
• W2921000372 date "2015-01-20" @default.
• W2921000372 modified "2023-09-25" @default.
• W2921000372 title "Awareness of KRAS testing by oncologists and panitumumab use in colorectal cancer patients: A European survey." @default.
• W2921000372 doi "https://doi.org/10.1200/jco.2015.33.3_suppl.547" @default.
• W2921000372 hasPublicationYear "2015" @default.
• W2921000372 type Work @default.
• W2921000372 sameAs 2921000372 @default.
• W2921000372 citedByCount "0" @default.
• W2921000372 crossrefType "journal-article" @default.
• W2921000372 hasAuthorship W2921000372A5020456711 @default.
• W2921000372 hasAuthorship W2921000372A5025634287 @default.
• W2921000372 hasAuthorship W2921000372A5031480761 @default.
• W2921000372 hasAuthorship W2921000372A5056028552 @default.
• W2921000372 hasAuthorship W2921000372A5067038598 @default.
• W2921000372 hasAuthorship W2921000372A5067647558 @default.
• W2921000372 hasAuthorship W2921000372A5069539916 @default.
• W2921000372 hasAuthorship W2921000372A5074765601 @default.
• W2921000372 hasAuthorship W2921000372A5090671983 @default.
• W2921000372 hasAuthorship W2921000372A5091162361 @default.
• W2921000372 hasConcept C121608353 @default.
• W2921000372 hasConcept C126322002 @default.
• W2921000372 hasConcept C143998085 @default.
• W2921000372 hasConcept C21790070 @default.
• W2921000372 hasConcept C2778332735 @default.
• W2921000372 hasConcept C2781187634 @default.
• W2921000372 hasConcept C512399662 @default.
• W2921000372 hasConcept C526805850 @default.
• W2921000372 hasConcept C71924100 @default.
• W2921000372 hasConceptScore W2921000372C121608353 @default.
• W2921000372 hasConceptScore W2921000372C126322002 @default.
• W2921000372 hasConceptScore W2921000372C143998085 @default.
• W2921000372 hasConceptScore W2921000372C21790070 @default.
• W2921000372 hasConceptScore W2921000372C2778332735 @default.
• W2921000372 hasConceptScore W2921000372C2781187634 @default.
• W2921000372 hasConceptScore W2921000372C512399662 @default.
• W2921000372 hasConceptScore W2921000372C526805850 @default.
• W2921000372 hasConceptScore W2921000372C71924100 @default.
• W2921000372 hasIssue "3_suppl" @default.
• W2921000372 hasLocation W29210003721 @default.
• W2921000372 hasOpenAccess W2921000372 @default.
• W2921000372 hasPrimaryLocation W29210003721 @default.
• W2921000372 hasRelatedWork W2133128087 @default.
• W2921000372 hasRelatedWork W2343091550 @default.
• W2921000372 hasRelatedWork W2589642515 @default.
• W2921000372 hasRelatedWork W2768563229 @default.
• W2921000372 hasRelatedWork W2987507797 @default.
• W2921000372 hasRelatedWork W3094547569 @default.
• W2921000372 hasRelatedWork W3180628252 @default.
• W2921000372 hasRelatedWork W4290998609 @default.
• W2921000372 hasRelatedWork W4318274231 @default.
• W2921000372 hasRelatedWork W4328049839 @default.
• W2921000372 hasVolume "33" @default.
• W2921000372 isParatext "false" @default.
• W2921000372 isRetracted "false" @default.
• W2921000372 magId "2921000372" @default.
• W2921000372 workType "article" @default.